Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and Ribociclib

5 Jul 2023

Abstract excerpt

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) play a crucial role in cancer treatment, particularly in breast cancer, and their mechanism of drug resistance is a topic of global interest in research. Hence, it is vital to comprehend the distinctions between various CDK4/6i, including their mechanisms of action and resistance mechanisms. This article aims to summarize the metabolic and transport variations as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37475713
DOI: 10.3389/fphar.2023.1212986

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differences in metabolic transport and resistance mechanisms of Abemaciclib, Palbociclib, and RibociclibPMID 37475713Read ↗

CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological ConditionsSemantic proximity Read ↗

Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunitiesSemantic proximity Read ↗

Biological specificity of CDK4/6 inhibitors: dose response relationship,in vivosignaling, and composite response signatureSemantic proximity Read ↗

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclib.Semantic proximity Read ↗

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical PracticeSemantic proximity Read ↗

Exemestane plus everolimus and palbociclib in metastatic breast cancer: clinical response and genomic/transcriptomic determinants of resistance in a phase I/II trialSemantic proximity Read ↗

Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer.Semantic proximity Read ↗

Efficient inhibition of cell proliferation and promotion of apoptosis requires continuous treatment with abemaciclibSemantic proximity Read ↗

Effects of ABCB1 and ABCG2 polymorphisms on the pharmacokinetics of abemaciclibSemantic proximity Read ↗

Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformanceSemantic proximity Read ↗

Role of Differentially Expressed Proteins in Acquired Resistance to Cdk4/6 Inhibitor in Breast CancerSemantic proximity Read ↗

Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.